EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Catalyst Biosciences's Enterprise Value is €-2.09 Mil.
Catalyst Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 was €-12.49 Mil. Therefore, Catalyst Biosciences's EV-to-FCF for today is 0.17.
The historical rank and industry rank for Catalyst Biosciences's EV-to-FCF or its related term are showing as below:
FRA:HGF2'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.86 Med: 0.13 Max: 3.84
Current: 0.17
During the past 13 years, the highest EV-to-FCF of Catalyst Biosciences was 3.84. The lowest was -6.86. And the median was 0.13.
FRA:HGF2's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 6.29
vs FRA:HGF2: 0.17
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Catalyst Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Catalyst Biosciences's EV-to-FCF
For the Biotechnology subindustry, Catalyst Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Biosciences's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Catalyst Biosciences's EV-to-FCF falls into.
Catalyst Biosciences's current Enterprise Value is €-2.09 Mil.
Catalyst Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-12.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Catalyst Biosciences's PE Ratio for today is calculated as:
Catalyst Biosciences's share price for today is €7.403999.
Catalyst Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.301.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Catalyst Biosciences EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Catalyst Biosciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Catalyst Biosciences (FRA:HGF2) Business Description
Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. It mainly focuses on developing novel medicines to address serious medical conditions for individuals in need of treatment options. The company emphasizes product development efforts in the field of hemostasis and to develop valuable therapies for individuals with hemophilia. It is engaged in the clinical development of improved, next-generation subcutaneous prophylaxis using enhanced potency Factor VIIa and Factor IX variants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:HGF2 has been successfully added to your 